Pyrotinib: all 113 studies that test it
Page 2 of 2. Open to participants first (55), then studies with results posted, then the rest; newest registration first within each.
- Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast CancerStatus unknownNCT03756064Not applicable
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.CompletedNCT03735966Phase 2
- A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast CancerActive, not recruitingNCT03691051Phase 2
- Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast CancerCompletedNCT03588091Phase 3
- Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerStatus unknownNCT03412383Phase 2
- Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)Status unknownNCT03080805Phase 3
- A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast CancerStatus unknownNCT02973737Phase 3
- A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 MutationCompletedNCT02834936Phase 2
- Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung CancerStatus unknownNCT02535507Phase 2
- Phase I Study of Pyrotinib in Patients With HER2-positive Solid TumorsStatus unknownNCT02500199Phase 1
- A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or TrastuzumabStatus unknownNCT02422199Phase 1/2
- Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerStatus unknownNCT02378389Phase 1
- Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast CancerCompletedNCT01937689Phase 1